Femtogenix Ltd. engages in the research and development of next generation DNA-interactive payload molecules for use in antibody-drug conjugates. Its platform allows us to design molecules capable of binding reversibly and/or irreversibly to DNA, in a sequence-interactive manner, leading to exquisite cytotoxicity toward tumour cells. The company was founded by Chris Keightley, David Thurston, Khondaker Miraz Rahman, and Paul Jackson in 2015 and is headquartered in Welwyn Garden City, the United Kingdom.
Transcriptogen Ltd. operates as a drug discovery company to exploit the use of small molecules to inhibit the interaction of transcription factors (TFs) with their cognate DNA-recognition site, thus down-regulating or inhibiting the transcription of disease-related genes. The firm develops and discovers anti-cancer drugs. The company was founded by Khondaker Miraz Rahman, Paul Jackson, and Sheraz Gul and is headquartered in Bath, the United Kingdom.